Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...

Wegovy, a semaglutide injection, aids in weight loss by suppressing appetite and boosting metabolism, now available in South ...

Weight Watchers va-t-il survivre à la révolution des médicaments coupe-faim ? En France, WW va se délester de tous ses ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Here are the stocks that have reflected the key market trends of 2024 and have been closely watched by investors.

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

During Q3 2024, the Lazard International Strategic Equity Portfolio rose 5.5% (net), lagging the MSCI EAFE Index. Click here ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...